Lineage Cell Therapeutics (LCTX) Short-term Investments (2017 - 2026)

Lineage Cell Therapeutics' Short-term Investments history runs 10 years deep, the most recent figure standing at $17.4 million for Q1 2026.

• In Q1 2026, Short-term Investments rose 91700.0% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $17.4 million (up 91700.0% YoY), while the FY2025 annual figure was $15.0 million, up 643.55% from the prior year.
• Short-term Investments for Q1 2026 stood at $17.4 million, up from $15.0 million in the prior quarter.
• The five-year high for Short-term Investments was $46.5 million in Q4 2022, with the low at $17000.0 in Q2 2025.
• The 5-year median for Short-term Investments is $5.0 million (2024), against an average of $11.3 million.
• The sharpest annual moves came in 2023 and 2026: Short-term Investments tumbled 99.89% in 2023, then jumped 91700.0% in 2026.
• Lineage Cell Therapeutics' Short-term Investments stood at $46.5 million in 2022, then sank by 99.89% to $50000.0 in 2023, then jumped by 3932.0% to $2.0 million in 2024, then soared by 643.55% to $15.0 million in 2025, then gained by 16.36% to $17.4 million in 2026.
• Business Quant data shows LCTX's Short-term Investments at $17.4 million in Q1 2026, $15.0 million in Q4 2025, and $23000.0 in Q3 2025.